In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Angiotensin Converting Enzyme in Sarcoidosis

Inhibitors of Angiotensin-converting Enzyme or Blockers of Angiotensin-2 Receptor in COVID-19 Patients with Comorbid Cardiovascular or Pulmonary Diseases

  Following the skyrocketing spread of SARS-CoV-2 into almost all the countries over five continents, diverse clinical strategies are urgently needed to defeat its pandemic, considering that an magic-bullet antiviral vaccine or treatment is presently unavailable. WHO later proclaimed the viral outbreak as a pandemic. Despite this fast speed of the pandemic, any recommended treatment must first...

Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.

Studies of 1st trimester exposure to ACE inhibitors and angiotensin receptor blockers examining teratogenicity have shown conflicting results. We systematically reviewed the literature and performed a meta-analysis evaluating the risk of major malformations. For the meta-analysis, we included studies comparing 1st trimester exposure to no exposure, or to exposure to other antihypertensives. Add...

impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on mortality of coronary artery bypass grafting

background: there is controversy over the potential benefits/harms of the usage of angiotensin-converting enzyme inhibitors (aceis) or angiotensin receptor blockers (arbs) as regards the postoperative mortality of coronary artery bypass grafting (cabg). this study investigates the correlation between the in-hospital mortality of cabg and the preoperative administration of acei/arb. methods: out...

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.

BACKGROUND Angiotensin-converting enzyme 2 (ACE2) has emerged as a novel regulator of cardiac function and arterial pressure by converting angiotensin II (Ang II) into the vasodilator and antitrophic heptapeptide, angiotensin-(1-7) [Ang-(1-7)]. As the only known human homolog of ACE, the demonstration that ACE2 is insensitive to blockade by ACE inhibitors prompted us to define the effect of ACE...